Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04855305 |
Recruitment Status :
Recruiting
First Posted : April 22, 2021
Last Update Posted : April 17, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Interstitial Lung Diseases | Drug: Hyperpolarized 129Xe | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 147 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease |
Actual Study Start Date : | November 12, 2021 |
Estimated Primary Completion Date : | March 31, 2025 |
Estimated Study Completion Date : | March 31, 2025 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Patients with Interstitial Lung Disease |
Drug: Hyperpolarized 129Xe
Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds. |
Active Comparator: Healthy Volunteers |
Drug: Hyperpolarized 129Xe
Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds. |
- Thoracic cavity volume measured in liters. [ Time Frame: 4 years ]
- RBC/barrier signal ratio (unitless). [ Time Frame: 4 years ]
- Coefficient of repeatability of RBC/barrier signal ratio (unitless). [ Time Frame: 4 years ]
- Echo time to separate RBC and barrier signals by 90 degrees (ms). [ Time Frame: 4 years ]
- Population-wide RBC/barrier signal ratio (unitless). [ Time Frame: 4 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion/Exclusion Criteria for Healthy Volunteers
Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- Outpatients of either gender, age greater than or equal to 18 years
- Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.)
- Subject has no diagnosed pulmonary conditions
- Subject has not smoked in the previous 5 years
- Smoking history, if any, is less than or equal to 5 pack-years
- No history of using other inhaled products more than 1 time per week for > 1 year
Exclusion Criteria: Subjects presenting with any of the following will not be included in the trial:
- Subject is less than 18 years old
- MRI is contraindicated based on responses to MRI screening questionnaire
- Subject is pregnant or lactating
- Resting oxygen saturation on room air <90%
- Respiratory illness of a bacterial or viral etiology within 30 days of MRI
- Subject has history of any known ventricular cardiac arrhythmia
- Subject has history of cardiac arrest within the last year
- Subject does not fit into Xe vest coil used for MRI 129
- Subject cannot hold his/her breath for 15 seconds
- Subject deemed unlikely to be able to comply with instructions during imaging
- Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
Inclusion/Exclusion Criteria for Subjects with Interstitial Lung Disease
Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment in the trial:
- Outpatients of either gender, age greater than or equal to 18 years
- Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.)
- Clinical diagnosis of Interstitial Lung Disease made by a board certified pulmonologist using established criteria. We will not exclude individuals based on ILD type or severity of disease with the exception of the below criteria
Exclusion Criteria: Subjects presenting with any of the following will not be included in the trial:
- Subject is less than 18 years old
- MRI is contraindicated based on responses to MRI screening questionnaire
- Subject is pregnant or lactating
- Resting oxygen saturation <90% on supplemental oxygen
- Respiratory illness of a bacterial or viral etiology within 30 days of MRI
- Subject has history of any known ventricular cardiac arrhythmia.
- Subject has history of cardiac arrest within the last year
- Subject does not fit into Xe vest coil used for MRI 129
- Subject cannot hold his/her breath for 15 seconds
- Subject deemed unlikely to be able to comply with instructions during imaging
- Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04855305
Contact: Bastiaan Driehuys, PhD | 919-684-7786 | bastiaan.driehuys@duke.edu |
United States, Iowa | |
University of Iowa | Recruiting |
Iowa City, Iowa, United States, 52242 | |
Contact: Sean Fain 319-356-4832 Sean-fain@uiowa.edu | |
United States, North Carolina | |
Duke University Medical Center | Recruiting |
Durham, North Carolina, United States, 27710 | |
Contact: Jennifer Korzekwinski 919-681-7362 jennifer.korzekwinski@duke.edu | |
Contact: Cody Blanton 919-668-7575 cody.blanton@duke.edu | |
Principal Investigator: Joseph Mammarappallil, MD | |
Sub-Investigator: Bastiaan Driehuys, PhD | |
United States, Ohio | |
University of Cincinnati | Recruiting |
Cincinnati, Ohio, United States, 45219 | |
Contact: Nishant Gupta 513-558-4831 guptans@ucmail.uc.edu | |
Principal Investigator: Nishant Gupta | |
Cincinnati Children's Hospital Medical Center | Recruiting |
Cincinnati, Ohio, United States, 45229 | |
Contact: Zackary Cleveland 513-803-7186 zackary.cleveland@cchmc.org | |
Principal Investigator: Zackary Cleveland |
Principal Investigator: | Joseph Mammarappallil, MD | Duke University |
Responsible Party: | Bastiaan Driehuys, Professor of Radiology, Duke University |
ClinicalTrials.gov Identifier: | NCT04855305 |
Other Study ID Numbers: |
Pro00107570 R01HL126771 ( U.S. NIH Grant/Contract ) |
First Posted: | April 22, 2021 Key Record Dates |
Last Update Posted: | April 17, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | A major focus of this work is sharing and dissemination of the image acquisition and analysis methods we develop as well as standard operating procedures for 129Xe MRI. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
Time Frame: | A major focus of this work is sharing and dissemination of the image acquisition and analysis methods we develop as well as standard operating procedures for 129Xe MRI. In all instances we will adhere to the NIH Sharing Policies and Related Guidance on NIH-Funded Research Resources for Recipients of NIH Grants and Contracts on Obtaining (https://grants.nih.gov/policy/sharing.htm) and Disseminating Biomedical Research Re-sources (issued December 1999). However, we intend to greatly exceed these requirements, making as much of our work freely available to the broader research community either before, or immediately after publication of manuscripts, as well as through PubMedCentral. While we we will provide relevant protocols upon request at any time, we further intend to pursue several proactive data sharing mechanisms. |
Access Criteria: | We are committed to making de-identified datasets and image analysis available to to qualified investigators. When required scientifically, data including identifiers will be shared under an agreement that provides for: (1) a commitment to using data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data appropriately; and (3) a commitment to destroying or returning the data after analyses are completed. |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Lung Diseases Lung Diseases, Interstitial Respiratory Tract Diseases |